Management
Academic Leadership co-directed by Dr. Aleix Prat and Dr. Teresa Macarulla
The IPO Chair, led by its director, Prof. Aleix Prat, was established with the aim of revolutionizing the application of precision medicine in the field of oncology. To achieve this goal, innovation, excellence, knowledge and collaboration in teaching and research will be promoted, with the aim of transforming the treatment of cancer and improving the lives of patients.
Dr. Aleix Prat is a medical oncologist, researcher, educator and entrepreneur, internationally recognized for his contributions to precision oncology, especially in breast cancer. He completed a medical oncology fellowship at Hospital Vall d'Hebron (2004-2008) under the supervision of Dr. Josep Baselga and continued his education in the United States (2008-2012). From 2014 to 2022, he led the Medical Oncology Department of Hospital Clínic de Barcelona, and since 2023 he has been the director of the Institute of Cancer and Blood Diseases of the same centre. Since 2024, he also leads the Clinic Barcelona Comprehensive Cancer Centre.
Dr. Prat is a senior lecturer in the Department of Medicine at the University of Barcelona and has a translational research laboratory at the Hospital Clínic, where he has led the development of innovative diagnostic tests such as HER2DX and TNBC-DX. He has published more than 300 articles in high-impact scientific journals, has led numerous clinical trials, and is a regular guest speaker at major conferences around the world.
With his 360° view of the oncology field, ranging from basic and translational research to clinical application and the development of new technologies, Dr. Prat works tirelessly to improve the treatment and prognosis of cancer patients.
Dr. Prat is a senior lecturer in the Department of Medicine at the University of Barcelona and has a translational research laboratory at the Hospital Clínic, where he has led the development of innovative diagnostic tests such as HER2DX and TNBC-DX. He has published more than 300 articles in high-impact scientific journals, has led numerous clinical trials, and is a regular guest speaker at major conferences around the world.
With his 360° view of the oncology field, ranging from basic and translational research to clinical application and the development of new technologies, Dr. Prat works tirelessly to improve the treatment and prognosis of cancer patients.
The IPO Chair, led by its director, Prof. Aleix Prat, was established with the aim of revolutionizing the application of precision medicine in the field of oncology. To achieve this goal, innovation, excellence, knowledge and collaboration in teaching and research will be promoted, with the aim of transforming the treatment of cancer and improving the lives of patients.
Dr. Teresa Macarulla is a medical oncologist with expertise in gastrointestinal tumors, with a particular focus on hepatobiliopancreatic cancers. She obtained her medical degree from the Universitat Autònoma de Barcelona and completed her MIR residency training in Medical Oncology at the Hospital de Sant Pau i la Santa Creu. She also carried out a research fellowship at Memorial Sloan Kettering Cancer Center (New York), focused on digestive tumors. At the Vall d’Hebron Institute of Oncology, she served as Head of the Gastrointestinal Tumors Section and as Principal Investigator at VHIO (Upper GI Cancer Translational Research Group).
She currently heads the Department of Medical Oncology at Hospital Clínic de Barcelona, where she leads clinical trials and translational research projects aimed at personalized medicine. She is an Associate Professor at the University of Barcelona and Head of the Upper Gastrointestinal Cancer Translational Oncology Research Group at FRCB/IDIBAPS. She has been principal investigator in international studies that have contributed to the approval of new treatments for pancreatic and biliary cancers, including combinations with chemotherapy and targeted therapies. Author of numerous publications in high-impact journals such as The Lancet and Annals of Oncology, her research focuses on biomarkers, EGFR inhibitors, and innovative strategies such as liquid biopsy.
With a comprehensive approach that integrates clinical practice and research, Dr. Macarulla works to improve the diagnosis, treatment, and prognosis of patients with complex gastrointestinal tumors.
She currently heads the Department of Medical Oncology at Hospital Clínic de Barcelona, where she leads clinical trials and translational research projects aimed at personalized medicine. She is an Associate Professor at the University of Barcelona and Head of the Upper Gastrointestinal Cancer Translational Oncology Research Group at FRCB/IDIBAPS. She has been principal investigator in international studies that have contributed to the approval of new treatments for pancreatic and biliary cancers, including combinations with chemotherapy and targeted therapies. Author of numerous publications in high-impact journals such as The Lancet and Annals of Oncology, her research focuses on biomarkers, EGFR inhibitors, and innovative strategies such as liquid biopsy.
With a comprehensive approach that integrates clinical practice and research, Dr. Macarulla works to improve the diagnosis, treatment, and prognosis of patients with complex gastrointestinal tumors.
News
